[go: up one dir, main page]

AR020876A1 - Compuestos multienlazantes del canal de calcio, una composicion farmaceutica, uso de dichos compuestos para la manufactura de un medicamento, un metodopara identificar compuestos multimericos ligantes que poseen propiedades multienlazantes, una biblioteca, compuestos ligantes multimericos, y un meto - Google Patents

Compuestos multienlazantes del canal de calcio, una composicion farmaceutica, uso de dichos compuestos para la manufactura de un medicamento, un metodopara identificar compuestos multimericos ligantes que poseen propiedades multienlazantes, una biblioteca, compuestos ligantes multimericos, y un meto

Info

Publication number
AR020876A1
AR020876A1 ARP990102696A ARP990102696A AR020876A1 AR 020876 A1 AR020876 A1 AR 020876A1 AR P990102696 A ARP990102696 A AR P990102696A AR P990102696 A ARP990102696 A AR P990102696A AR 020876 A1 AR020876 A1 AR 020876A1
Authority
AR
Argentina
Prior art keywords
compounds
binding
calcium channel
manufacture
pharmaceutical composition
Prior art date
Application number
ARP990102696A
Other languages
English (en)
Spanish (es)
Original Assignee
Advanced Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Inc filed Critical Advanced Medicine Inc
Publication of AR020876A1 publication Critical patent/AR020876A1/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
ARP990102696A 1998-06-08 1999-06-08 Compuestos multienlazantes del canal de calcio, una composicion farmaceutica, uso de dichos compuestos para la manufactura de un medicamento, un metodopara identificar compuestos multimericos ligantes que poseen propiedades multienlazantes, una biblioteca, compuestos ligantes multimericos, y un meto AR020876A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8846598P 1998-06-08 1998-06-08
US9306898P 1998-07-16 1998-07-16
US10386698P 1998-10-12 1998-10-12

Publications (1)

Publication Number Publication Date
AR020876A1 true AR020876A1 (es) 2002-06-05

Family

ID=27375969

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102696A AR020876A1 (es) 1998-06-08 1999-06-08 Compuestos multienlazantes del canal de calcio, una composicion farmaceutica, uso de dichos compuestos para la manufactura de un medicamento, un metodopara identificar compuestos multimericos ligantes que poseen propiedades multienlazantes, una biblioteca, compuestos ligantes multimericos, y un meto

Country Status (7)

Country Link
EP (1) EP1085863A1 (fr)
JP (1) JP2002517440A (fr)
AR (1) AR020876A1 (fr)
AU (1) AU4549399A (fr)
CA (1) CA2318901A1 (fr)
SG (1) SG80038A1 (fr)
WO (1) WO1999063992A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101909B2 (en) 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
ES2334029T3 (es) 2003-05-15 2010-03-04 Roskamp Research Llc Procedimiento para producir medicamentos para reducir la deposicion de amiloide, la neurotoxicidad de amiloide y la microgliosis.
DK2214666T3 (da) 2007-10-05 2014-01-27 Alzheimer S Inst Of America Inc Fremgangsmåde til reducering af amyloid-afsætning, amyloid-neurotoksicitet og mikrogliose med (-)-nilvadipin-enantiomer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3042769A1 (de) * 1980-11-13 1982-06-09 Bayer Ag, 5090 Leverkusen C-3 verknuepfte 1,4-dihydropyridine, ihre verwendung in arzneimitteln und verfahren zu ihrer herstellung
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
US4771057A (en) * 1986-02-03 1988-09-13 University Of Alberta Reduced pyridyl derivatives with cardiovascular regulating properties
AU8730691A (en) * 1990-09-28 1992-04-28 Neorx Corporation Polymeric carriers for release of covalently linked agents
KR100517210B1 (ko) * 1994-12-12 2006-06-07 오메로스 코포레이션 통증,염증및경련억제용관주용액
WO1996033972A1 (fr) * 1995-04-28 1996-10-31 Glaxo Group Limited Procedes de synthese de divers ensembles de pyridines, pyrimidines, derives 1,4-dihydro de ces composes et derives de piperidine
NZ280378A (en) * 1995-11-01 1998-04-27 Apotex Inc 4-phenyl-1,4-dihydropyridine-3,5-dicarboxylic acid compounds, preparation, intermediate compounds
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
US6403305B1 (en) * 1997-02-06 2002-06-11 Cornell Research Foundation, Inc. Methods of identifying peptide agonists or negative antagonists of a G protein coupled receptor

Also Published As

Publication number Publication date
EP1085863A4 (fr) 2001-03-28
SG80038A1 (en) 2001-04-17
WO1999063992A1 (fr) 1999-12-16
JP2002517440A (ja) 2002-06-18
WO1999063992A9 (fr) 2002-08-22
EP1085863A1 (fr) 2001-03-28
CA2318901A1 (fr) 1999-12-16
AU4549399A (en) 1999-12-30
WO1999063992A8 (fr) 2001-02-22

Similar Documents

Publication Publication Date Title
DE69830336D1 (de) Ein kovalentes konjugat von clozapine und einer fettsäure und dessen verwendung zur behandlung von schizophrenie
AR020021A1 (es) Composicion para el tratamiento de cancer usando aceites esenciales de plantas naturales con moduladores de transduccion de senal
ATE322266T1 (de) Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
ATE252919T1 (de) Zusammensetzungen und ihre verwendung zur verhütung von verklebungen zwischen körpergewebe
ES2185711T3 (es) 1,4-benzotiazepina-1,1-dioxidoshipolipimemicos.
AR018630A1 (es) Compuesto de multifijacion, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento, metodo para identificar dicho compuestoy biblioteca de dicho compuesto
BR0100046A (pt) Copolìmeros reticulados solúveis em água ou intumescìveis em água
FI972366A7 (fi) Lipopolyamiinit transfektoivina aineina ja niiden farmaseuttinen käytt ö
BR0112969A (pt) Método de utilização de dicetopiperazinas e composições contendo-as
EE200000468A (et) Ühendid, nende kasutamine ja farmatseutiline kompositsioon
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
TR200000927T2 (tr) Prostaglandin agonistleri ve kemik bozukluklarının tedavisi
NI200600290A (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
FI973039A0 (fi) Uusia farnesyylitransferaasin inhibiittoreita, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
ES2149044T3 (es) Metanosulfonato de paroxetina.
EE200000225A (et) Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon
EA200300532A1 (ru) Способ и состав для связывания ацетальдегида в слюне, желудке и толстой кишке
BR9916004A (pt) Inibidores de proteinase c de pró-colágeno
ES2159403T3 (es) Poliuretanos termoplasticos que contienen principios activos.
ES2192704T3 (es) Innovadoras composiciones farmaceuticas.
AR020876A1 (es) Compuestos multienlazantes del canal de calcio, una composicion farmaceutica, uso de dichos compuestos para la manufactura de un medicamento, un metodopara identificar compuestos multimericos ligantes que poseen propiedades multienlazantes, una biblioteca, compuestos ligantes multimericos, y un meto
PT1263426E (pt) Preparacoes para a remocao nao traumatica de uma unha
PT1150681E (pt) Utilizacao de uma composicao farmaceutica que contem desoxipeganina para o tratamento da dependencia da nicotina
NO991867L (no) Biaromatiske forbindelser bundet via et heteroetynylenradikal, og farmas°ytiske og kosmetiske sammensetninger inneholdende dem
PT920336E (pt) Pesticidas que compreendem alcaloides da benzofenantridina